New York State Common Retirement Fund’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.09M | Buy |
25,243
+6,861
| +37% | +$717K | ﹤0.01% | 1284 |
|
|
2026
Q1 | $1.94M | Hold |
18,382
| – | – | ﹤0.01% | 1398 |
|
|
2025
Q4 | $1.61M | Sell |
18,382
-1,200
| -6% | -$98.2K | ﹤0.01% | 1495 |
|
|
2025
Q3 | $1.3M | Hold |
19,582
| – | – | ﹤0.01% | 1587 |
|
|
2025
Q2 | $1.08M | Hold |
19,582
| – | – | ﹤0.01% | 1636 |
|
|
2025
Q1 | $947K | Buy |
19,582
+1,700
| +10% | +$71.2K | ﹤0.01% | 1652 |
|
|
2024
Q4 | $690K | Sell |
17,882
-2,300
| -11% | -$100K | ﹤0.01% | 1828 |
|
|
2024
Q3 | $908K | Sell |
20,182
-2,900
| -13% | -$117K | ﹤0.01% | 1713 |
|
|
2024
Q2 | $800K | Buy |
23,082
+38
| +0.2% | +$1.11K | ﹤0.01% | 1861 |
|
|
2024
Q1 | $667K | Sell |
23,044
-59
| -0.3% | -$1.6K | ﹤0.01% | 1959 |
|
|
2023
Q4 | $530K | Sell |
23,103
-98
| -0.4% | -$1.72K | ﹤0.01% | 2075 |
|
|
2023
Q3 | $387K | Buy |
23,201
+237
| +1% | +$4.6K | ﹤0.01% | 2156 |
|
|
2023
Q2 | $634K | Sell |
22,964
-4,728
| -17% | -$118K | ﹤0.01% | 1968 |
|
|
2023
Q1 | $637K | Buy |
27,692
+19
| +0.1% | +$319 | ﹤0.01% | 2055 |
|
|
2022
Q4 | $302K | Sell |
27,673
-24
| -0.1% | -$202 | ﹤0.01% | 2550 |
|
|
2022
Q3 | $233K | Buy |
27,697
+5,397
| +24% | +$51.1K | ﹤0.01% | 2708 |
|
|
2022
Q2 | $176K | Sell |
22,300
-10,906
| -33% | -$132K | ﹤0.01% | 2850 |
|
|
2022
Q1 | $786K | Buy |
33,206
+45
| +0.1% | +$1.27K | ﹤0.01% | 2221 |
|
|
2021
Q4 | $1.13M | Buy |
33,161
+3,223
| +11% | +$102K | ﹤0.01% | 2062 |
|
|
2021
Q3 | $531K | Sell |
29,938
-5,852
| -16% | -$249K | ﹤0.01% | 2435 |
|
|
2021
Q2 | $1.61M | Buy |
35,790
+8,290
| +30% | +$274K | ﹤0.01% | 1999 |
|
|
2021
Q1 | $712K | Hold |
27,500
| – | – | ﹤0.01% | 2281 |
|
|
2020
Q4 | $554K | Buy |
27,500
+6,600
| +32% | +$142K | ﹤0.01% | 2306 |
|
|
2020
Q3 | $409K | Hold |
20,900
| – | – | ﹤0.01% | 2308 |
|
|
2020
Q2 | $369K | Buy |
20,900
+5,400
| +35% | +$67.7K | ﹤0.01% | 2368 |
|
|
2020
Q1 | $109K | Hold |
15,500
| – | – | ﹤0.01% | 2739 |
|
|
2019
Q4 | $109K | Hold |
15,500
| – | – | ﹤0.01% | 2980 |
|
|
2019
Q3 | $186K | Hold |
15,500
| – | – | ﹤0.01% | 2808 |
|
|
2019
Q2 | $188K | Buy |
+15,500
| New | +$171K | ﹤0.01% | 2848 |
|
|
2018
Q2 | – | Sell |
-13,600
| Closed | -$117K | – | 3203 |
|
|
2018
Q1 | $117K | Buy |
13,600
+3,400
| +33% | +$64K | ﹤0.01% | 2923 |
|
|
2017
Q4 | $212K | Buy |
10,200
+2,600
| +34% | +$46.1K | ﹤0.01% | 2734 |
|
|
2017
Q3 | $134K | Hold |
7,600
| – | – | ﹤0.01% | 2935 |
|
|
2017
Q2 | $86K | Sell |
7,600
-1
| -0% | -$11 | ﹤0.01% | 3107 |
|
|
2017
Q1 | $97K | Buy |
+7,601
| New | +$122K | ﹤0.01% | 2974 |
|
Other funds holding PTGX
SIMG
SAM
NFT
New York State Common Retirement Fund's PTGX Position: Q2 2026 in Review
New York State Common Retirement Fund increased its Protagonist Therapeutics (PTGX) stake by 37% in Q2 2026, buying an estimated $717K and bringing the position to 25,243 shares worth $3.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1284.
New York State Common Retirement Fund first reported a position in PTGX in Q1 2017 and has held it in 34 quarters since. 92 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.
- New York State Common Retirement Fund held 25,243 shares of Protagonist Therapeutics worth $3.09M as of Q2 2026.
- New York State Common Retirement Fund bought 6,861 Protagonist Therapeutics shares in Q2 2026, an estimated $717K.
- Protagonist Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1284 holding.
- New York State Common Retirement Fund first reported a position in Protagonist Therapeutics in Q1 2017 and has held it in 34 quarters since.
- 92 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.